论文部分内容阅读
为提高临床大肠癌转移的预测水平,术前联合检测14例大肠癌患者血清癌胚抗原(CEA)和糖链抗原50(CA-50)两种 肿瘤标志物。结果显示,CEA和CA-50随大肠癌Dukes分期的进展血清浓度逐渐升高,两者在大肠癌各期的阳性率分别为:CEA 中A期33.3％(2/6)、B期37.5％(3/8)、C期66.7%(12、18)、D期75.0％(9/12),CA—50A期16.6％(1/6)、B期12.5%(1/8)、C 期55.5％(10/18)、D期75.0％(9/12),CEA+CA-50A期33.3%(2/6)、B期37.5％(3/8)、C期77.7％(14/18)、D期83.3%(10/ 12),CEA+CA-50与各单项阳性率比较均有显著性差异(P>0.05)。提示CEA与CA-50联合检测对大肠癌转移有较高的敏 感性,对术前预测大肠癌转移有一定临床价值。
To improve the predictive value of clinical colorectal cancer metastasis, two tumor markers, serum carcinoembryonic antigen (CEA) and carbohydrate antigen 50 (CA-50), were detected preoperatively in 14 patients with colorectal cancer. The results showed that the serum concentration of CEA and CA-50 gradually increased with the progress of Dukes staging of colorectal cancer. The positive rates of CEA and CA-50 in colorectal cancer were 33.3% (2/6) in stage A, 37.5% (3/8), 66.7% (12,18) in C, 75.0% (9/12) in D, 16.6% (1/6) in CA-50A and 12.5% 55.5% (10/18), 75.0% (9/12) in D stage, 33.3% (2/6) in CEA + CA-50A stage, 37.5% (3/8) in stage B, 77.7% ), 83.3% (10/12) in D stage, and CEA + CA-50 had significant difference with the individual positive rate (P> 0.05). These results suggest that the combination of CEA and CA-50 has a higher sensitivity for the metastasis of colorectal cancer and has some clinical value in predicting the metastasis of colorectal cancer before surgery.